These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 19337557

  • 21. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.
    Liuni A, Luca MC, Gori T, Parker JD.
    J Am Coll Cardiol; 2010 Mar 09; 55(10):1002-6. PubMed ID: 20202516
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
    Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group.
    Am J Cardiol; 2007 Jun 01; 99(11):1538-43. PubMed ID: 17531577
    [Abstract] [Full Text] [Related]

  • 30. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
    De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, Van Eyck D, Scheen A, Peuskens J.
    J Clin Psychiatry; 2006 Dec 01; 67(12):1889-96. PubMed ID: 17194266
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
    Rizos CV, Liberopoulos EN, Tellis K, DiNicolantonio JJ, Tselepis AD, Elisaf MS.
    Angiology; 2015 Jan 01; 66(1):36-42. PubMed ID: 24288364
    [Abstract] [Full Text] [Related]

  • 33. Rosuvastatin: a review of its use in the management of dyslipidemia.
    Scott LJ, Curran MP, Figgitt DP.
    Am J Cardiovasc Drugs; 2004 Jan 01; 4(2):117-38. PubMed ID: 15049723
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC.
    Clin Ther; 2013 Aug 01; 35(8):1186-98. PubMed ID: 23891363
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.